Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Flow Cytometry-Based Epitope Binning Using Competitive Binding Profiles for the Characterization of Monoclonal Antibodies against Cellular and Soluble Protein Targets.

Chan BM, Badh A, Berry KA, Grauer SA, King CT.

SLAS Discov. 2018 Aug;23(7):613-623. doi: 10.1177/2472555218774334. Epub 2018 May 21.

PMID:
29783865
2.

General error model for analysis of laser-induced incandescence signals.

Sipkens TA, Hadwin PJ, Grauer SJ, Daun KJ.

Appl Opt. 2017 Oct 20;56(30):8436-8445. doi: 10.1364/AO.56.008436.

PMID:
29091624
3.

Measurement-based meshing, basis selection, and prior assignment in chemical species tomography.

Grauer SJ, Hadwin PJ, Sipkens TA, Daun KJ.

Opt Express. 2017 Oct 16;25(21):25135-25148. doi: 10.1364/OE.25.025135.

PMID:
29041185
4.

Scaling of the Quantum Anomalous Hall Effect as an Indicator of Axion Electrodynamics.

Grauer S, Fijalkowski KM, Schreyeck S, Winnerlein M, Brunner K, Thomale R, Gould C, Molenkamp LW.

Phys Rev Lett. 2017 Jun 16;118(24):246801. doi: 10.1103/PhysRevLett.118.246801. Epub 2017 Jun 16.

PMID:
28665643
5.

Improving chemical species tomography of turbulent flows using covariance estimation.

Grauer SJ, Hadwin PJ, Daun KJ.

Appl Opt. 2017 May 1;56(13):3900-3912. doi: 10.1364/AO.56.003900.

PMID:
28463285
6.

Impact of antibody subclass and disulfide isoform differences on the biological activity of CD200R and βklotho agonist antibodies.

Grujic O, Stevens J, Chou RY, Weiszmann JV, Sekirov L, Thomson C, Badh A, Grauer S, Chan B, Graham K, Manchulenko K, Dillon TM, Li Y, Foltz IN.

Biochem Biophys Res Commun. 2017 May 13;486(4):985-991. doi: 10.1016/j.bbrc.2017.03.145. Epub 2017 Mar 28.

PMID:
28363871
7.

Bayesian approach to the design of chemical species tomography experiments.

Grauer SJ, Hadwin PJ, Daun KJ.

Appl Opt. 2016 Jul 20;55(21):5772-82. doi: 10.1364/AO.55.005772.

PMID:
27463937
8.

Kinetic limitation of chemical ordering in Bi2Te3-x Se x layers grown by molecular beam epitaxy.

Schreyeck S, Brunner K, Kirchner A, Bass U, Grauer S, Schumacher C, Gould C, Karczewski G, Geurts J, Molenkamp LW.

J Phys Condens Matter. 2016 Apr 13;28(14):145002. doi: 10.1088/0953-8984/28/14/145002. Epub 2016 Mar 10.

PMID:
26962934
9.

Magneto-optics of massive dirac fermions in bulk Bi2Se3.

Orlita M, Piot BA, Martinez G, Kumar NK, Faugeras C, Potemski M, Michel C, Hankiewicz EM, Brauner T, Drašar Č, Schreyeck S, Grauer S, Brunner K, Gould C, Brüne C, Molenkamp LW.

Phys Rev Lett. 2015 May 8;114(18):186401. Epub 2015 May 6.

PMID:
26001011
10.

MitoPark mice, an animal model of Parkinson's disease, show enhanced prepulse inhibition of acoustic startle and no loss of gating in response to the adenosine A(2A) antagonist SCH 412348.

Grauer SM, Hodgson R, Hyde LA.

Psychopharmacology (Berl). 2014 Apr;231(7):1325-37. doi: 10.1007/s00213-013-3320-5. Epub 2013 Oct 23.

PMID:
24150248
11.

Novel triazines as potent and selective phosphodiesterase 10A inhibitors.

Malamas MS, Stange H, Schindler R, Lankau HJ, Grunwald C, Langen B, Egerland U, Hage T, Ni Y, Erdei J, Fan KY, Parris K, Marquis KL, Grauer S, Brennan J, Navarra R, Graf R, Harrison BL, Robichaud A, Kronbach T, Pangalos MN, Brandon NJ, Hoefgen N.

Bioorg Med Chem Lett. 2012 Sep 15;22(18):5876-84. doi: 10.1016/j.bmcl.2012.07.076. Epub 2012 Jul 31.

PMID:
22902656
12.

Development and characterization of a human antibody reference panel against erythropoietin suitable for the standardization of ESA immunogenicity testing.

Mytych DT, Barger TE, King C, Grauer S, Haldankar R, Hsu E, Wu MM, Shiwalkar M, Sanchez S, Kuck A, Civoli F, Sun J, Swanson SJ.

J Immunol Methods. 2012 Aug 31;382(1-2):129-41. doi: 10.1016/j.jim.2012.05.013. Epub 2012 May 23.

PMID:
22634015
13.

Highly potent, selective, and orally active phosphodiesterase 10A inhibitors.

Malamas MS, Ni Y, Erdei J, Stange H, Schindler R, Lankau HJ, Grunwald C, Fan KY, Parris K, Langen B, Egerland U, Hage T, Marquis KL, Grauer S, Brennan J, Navarra R, Graf R, Harrison BL, Robichaud A, Kronbach T, Pangalos MN, Hoefgen N, Brandon NJ.

J Med Chem. 2011 Nov 10;54(21):7621-38. doi: 10.1021/jm2009138. Epub 2011 Oct 11.

PMID:
21988093
14.

Preclinical assessment of an adjunctive treatment approach for cognitive impairment associated with schizophrenia using the alpha7 nicotinic acetylcholine receptor agonist WYE-103914/SEN34625.

Marquis KL, Comery TA, Jow F, Navarra RL, Grauer SM, Pulicicchio C, Kelley C, Brennan JA, Roncarati R, Scali C, Haydar S, Ghiron C, Terstappen GC, Dunlop J.

Psychopharmacology (Berl). 2011 Dec;218(4):635-47. doi: 10.1007/s00213-011-2357-6. Epub 2011 Jun 4.

PMID:
21643676
15.

Novel alpha-7 nicotinic acetylcholine receptor agonists containing a urea moiety: identification and characterization of the potent, selective, and orally efficacious agonist 1-[6-(4-fluorophenyl)pyridin-3-yl]-3-(4-piperidin-1-ylbutyl) urea (SEN34625/WYE-103914).

Ghiron C, Haydar SN, Aschmies S, Bothmann H, Castaldo C, Cocconcelli G, Comery TA, Di L, Dunlop J, Lock T, Kramer A, Kowal D, Jow F, Grauer S, Harrison B, La Rosa S, Maccari L, Marquis KL, Micco I, Nencini A, Quinn J, Robichaud AJ, Roncarati R, Scali C, Terstappen GC, Turlizzi E, Valacchi M, Varrone M, Zanaletti R, Zanelli U.

J Med Chem. 2010 Jun 10;53(11):4379-89. doi: 10.1021/jm901692q.

PMID:
20465311
16.

The synthesis and biological evaluation of quinolyl-piperazinyl piperidines as potent serotonin 5-HT1A antagonists.

Childers WE Jr, Havran LM, Asselin M, Bicksler JJ, Chong DC, Grosu GT, Shen Z, Abou-Gharbia MA, Bach AC 3rd, Harrison BL, Kagan N, Kleintop T, Magolda R, Marathias V, Robichaud AJ, Sabb AL, Zhang MY, Andree TH, Aschmies SH, Beyer C, Comery TA, Day M, Grauer SM, Hughes ZA, Rosenzweig-Lipson S, Platt B, Pulicicchio C, Smith DE, Sukoff-Rizzo SJ, Sullivan KM, Adedoyin A, Huselton C, Hirst WD.

J Med Chem. 2010 May 27;53(10):4066-84. doi: 10.1021/jm1000908.

PMID:
20443629
17.

Phosphodiesterase 11A in brain is enriched in ventral hippocampus and deletion causes psychiatric disease-related phenotypes.

Kelly MP, Logue SF, Brennan J, Day JP, Lakkaraju S, Jiang L, Zhong X, Tam M, Sukoff Rizzo SJ, Platt BJ, Dwyer JM, Neal S, Pulito VL, Agostino MJ, Grauer SM, Navarra RL, Kelley C, Comery TA, Murrills RJ, Houslay MD, Brandon NJ.

Proc Natl Acad Sci U S A. 2010 May 4;107(18):8457-62. doi: 10.1073/pnas.1000730107. Epub 2010 Apr 19.

18.

WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity.

Brennan JA, Graf R, Grauer SM, Navarra RL, Pulicicchio CM, Hughes ZA, Lin Q, Wantuch C, Rosenzweig-Lipson S, Pruthi F, Lai M, Smith D, Goutier W, van de Neut M, Robichaud AJ, Rotella D, Feenstra RW, Kruse C, Broqua P, Beyer CE, McCreary AC, Pausch MH, Marquis KL.

J Pharmacol Exp Ther. 2010 Jan;332(1):190-201. doi: 10.1124/jpet.109.157388. Epub 2009 Oct 14.

PMID:
19828876
19.

The orphan GPCR, GPR88, modulates function of the striatal dopamine system: a possible therapeutic target for psychiatric disorders?

Logue SF, Grauer SM, Paulsen J, Graf R, Taylor N, Sung MA, Zhang L, Hughes Z, Pulito VL, Liu F, Rosenzweig-Lipson S, Brandon NJ, Marquis KL, Bates B, Pausch M.

Mol Cell Neurosci. 2009 Dec;42(4):438-47. doi: 10.1016/j.mcn.2009.09.007. Epub 2009 Sep 29.

PMID:
19796684
20.

Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia.

Rotella DP, McFarlane GR, Greenfield A, Grosanu C, Robichaud AJ, Denny RA, Feenstra RW, Núñez-García S, Reinders JH, Neut Mv, McCreary A, Kruse CG, Sullivan K, Pruthi F, Lai M, Zhang J, Kowal DM, Carrick T, Grauer SM, Navarra RL, Graf R, Brennan J, Marquis KL, Pausch MH.

Bioorg Med Chem Lett. 2009 Oct 1;19(19):5552-5. doi: 10.1016/j.bmcl.2009.08.050. Epub 2009 Aug 15.

PMID:
19720528
21.

Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia.

Grauer SM, Pulito VL, Navarra RL, Kelly MP, Kelley C, Graf R, Langen B, Logue S, Brennan J, Jiang L, Charych E, Egerland U, Liu F, Marquis KL, Malamas M, Hage T, Comery TA, Brandon NJ.

J Pharmacol Exp Ther. 2009 Nov;331(2):574-90. doi: 10.1124/jpet.109.155994. Epub 2009 Aug 6.

PMID:
19661377
22.

Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist.

Ring RH, Schechter LE, Leonard SK, Dwyer JM, Platt BJ, Graf R, Grauer S, Pulicicchio C, Resnick L, Rahman Z, Sukoff Rizzo SJ, Luo B, Beyer CE, Logue SF, Marquis KL, Hughes ZA, Rosenzweig-Lipson S.

Neuropharmacology. 2010 Jan;58(1):69-77. doi: 10.1016/j.neuropharm.2009.07.016. Epub 2009 Jul 15.

PMID:
19615387
23.

Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders.

Roncarati R, Scali C, Comery TA, Grauer SM, Aschmi S, Bothmann H, Jow B, Kowal D, Gianfriddo M, Kelley C, Zanelli U, Ghiron C, Haydar S, Dunlop J, Terstappen GC.

J Pharmacol Exp Ther. 2009 May;329(2):459-68. doi: 10.1124/jpet.108.150094. Epub 2009 Feb 17.

PMID:
19223665
24.

WAY-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics.

Grauer SM, Graf R, Navarra R, Sung A, Logue SF, Stack G, Huselton C, Liu Z, Comery TA, Marquis KL, Rosenzweig-Lipson S.

Psychopharmacology (Berl). 2009 May;204(1):37-48. doi: 10.1007/s00213-008-1433-z. Epub 2008 Dec 20.

PMID:
19107466
25.

Old and new pharmacology: positive allosteric modulation of the alpha7 nicotinic acetylcholine receptor by the 5-hydroxytryptamine(2B/C) receptor antagonist SB-206553 (3,5-dihydro-5-methyl-N-3-pyridinylbenzo[1,2-b:4,5-b']di pyrrole-1(2H)-carboxamide).

Dunlop J, Lock T, Jow B, Sitzia F, Grauer S, Jow F, Kramer A, Bowlby MR, Randall A, Kowal D, Gilbert A, Comery TA, Larocque J, Soloveva V, Brown J, Roncarati R.

J Pharmacol Exp Ther. 2009 Mar;328(3):766-76. doi: 10.1124/jpet.108.146514. Epub 2008 Dec 2.

PMID:
19050173
26.

ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities.

Liu F, Grauer S, Kelley C, Navarra R, Graf R, Zhang G, Atkinson PJ, Popiolek M, Wantuch C, Khawaja X, Smith D, Olsen M, Kouranova E, Lai M, Pruthi F, Pulicicchio C, Day M, Gilbert A, Pausch MH, Brandon NJ, Beyer CE, Comery TA, Logue S, Rosenzweig-Lipson S, Marquis KL.

J Pharmacol Exp Ther. 2008 Dec;327(3):827-39. doi: 10.1124/jpet.108.136580. Epub 2008 Aug 27.

PMID:
18753411
27.

Activation of estrogen receptor-beta regulates hippocampal synaptic plasticity and improves memory.

Liu F, Day M, Muñiz LC, Bitran D, Arias R, Revilla-Sanchez R, Grauer S, Zhang G, Kelley C, Pulito V, Sung A, Mervis RF, Navarra R, Hirst WD, Reinhart PH, Marquis KL, Moss SJ, Pangalos MN, Brandon NJ.

Nat Neurosci. 2008 Mar;11(3):334-43. doi: 10.1038/nn2057. Epub 2008 Feb 24.

PMID:
18297067
28.

Correlating efficacy in rodent cognition models with in vivo 5-hydroxytryptamine1a receptor occupancy by a novel antagonist, (R)-N-(2-methyl-(4-indolyl-1-piperazinyl)ethyl)-N-(2-pyridinyl)-cyclohexane carboxamide (WAY-101405).

Hirst WD, Andree TH, Aschmies S, Childers WE, Comery TA, Dawson LA, Day M, Feingold IB, Grauer SM, Harrison BL, Hughes ZA, Kao J, Kelly MG, van der Lee H, Rosenzweig-Lipson S, Saab AL, Smith DL, Sullivan K, Rizzo SJ, Tio C, Zhang MY, Schechter LE.

J Pharmacol Exp Ther. 2008 Apr;325(1):134-45. doi: 10.1124/jpet.107.133082. Epub 2008 Jan 8.

PMID:
18182558
29.
30.

Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist WAY-163909 in rodents.

Rosenzweig-Lipson S, Sabb A, Stack G, Mitchell P, Lucki I, Malberg JE, Grauer S, Brennan J, Cryan JF, Sukoff Rizzo SJ, Dunlop J, Barrett JE, Marquis KL.

Psychopharmacology (Berl). 2007 Jun;192(2):159-70. Epub 2007 Feb 13.

PMID:
17297636
31.

WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity.

Marquis KL, Sabb AL, Logue SF, Brennan JA, Piesla MJ, Comery TA, Grauer SM, Ashby CR Jr, Nguyen HQ, Dawson LA, Barrett JE, Stack G, Meltzer HY, Harrison BL, Rosenzweig-Lipson S.

J Pharmacol Exp Ther. 2007 Jan;320(1):486-96. Epub 2006 Oct 12.

PMID:
17038512
32.

Acute pericarditis. Evaluation and treatment of infectious and other causes.

Ross AM, Grauer SE.

Postgrad Med. 2004 Mar;115(3):67-70, 73-5. Review.

PMID:
15038256
33.
34.

Phase II, placebo-controlled trial of MRX115 (Aerosomes) for left heart and myocardial perfusion imaging.

Pantely GA, Joyce M, Grauer SE, Giraud GD, Shiota T, Sahn D.

Acad Radiol. 1998 Apr;5 Suppl 1:S66-8; discussion S72-4. No abstract available.

PMID:
9561047
35.

Dynamic cleft maxillary orthopedics and periosteoplasty: benefit or detriment?

Lukash FN, Schwartz M, Grauer S, Tuminelli F.

Ann Plast Surg. 1998 Apr;40(4):321-6; discussion 326-7.

PMID:
9555983
36.

Toxic methemoglobinemia after topical anesthesia for transesophageal echocardiography.

Grauer SE, Giraud GD.

J Am Soc Echocardiogr. 1996 Nov-Dec;9(6):874-6.

PMID:
8943448
37.

Myocardial imaging with a new transpulmonary lipid-fluorocarbon echo contrast agent: experimental studies in pigs.

Grauer SE, Pantely GA, Xu J, Ge S, Giraud GD, Shiota T, Sahn DJ.

Am Heart J. 1996 Nov;132(5):938-45.

PMID:
8892764
38.

MRX 115, an echocardiographic contrast agent, produces myocardial opacification after intravenous injection in primates: studies before and after occlusion of left anterior descending coronary artery.

Grauer SE, Xu J, Pantely GA, Ge S, Gong Z, Shiota T, Zhou X, Sahn DJ.

Acad Radiol. 1996 Aug;3 Suppl 2:S405-6. No abstract available.

PMID:
8796615
39.

Metabolic adaptation to a gradual reduction in myocardial blood flow.

Arai AE, Grauer SE, Anselone CG, Pantely GA, Bristow JD.

Circulation. 1995 Jul 15;92(2):244-52.

PMID:
7600657
40.

Metabolic aspects of hibernating myocardium.

Pantely GA, Arai AE, Grauer SE, Bristow JD.

Z Kardiol. 1995;84 Suppl 4:101-5. Review.

PMID:
8585260
41.

Spontaneous echo contrast and hemorheologic abnormalities in cerebrovascular disease.

Briley DP, Giraud GD, Beamer NB, Spear EM, Grauer SE, Edwards JM, Clark WM, Sexton GJ, Coull BM.

Stroke. 1994 Aug;25(8):1564-9.

PMID:
7518970
42.

Morphine induces an increase in extracellular serotonin in the rat diencephalon.

Grauer SM, Tao R, Auerbach SB.

Brain Res. 1992 Dec 25;599(2):277-82.

PMID:
1283972
43.

Microdialysis measurement of serotonin release in the central nervous system.

Auerbach SB, Wilkinson LO, Rui T, Grauer S, Rutter J.

J Chem Neuroanat. 1992 Jul-Aug;5(4):331-3. No abstract available.

PMID:
1388025
44.

Cord whole blood hyperviscosity: measurement, definition, incidence and clinical features.

Drew JH, Guaran RL, Grauer S, Hobbs JB.

J Paediatr Child Health. 1991 Dec;27(6):363-5.

PMID:
1756079
46.

Keratinizing and calcifying odontogenic cyst of the mandible: literature review and a case report.

Schwimmer AM, Barr CE, Grauer SJ.

Mt Sinai J Med. 1983 Nov-Dec;50(6):501-6. No abstract available.

PMID:
6607406
47.

Effect of lung denervation on development of pulmonary edema.

Grauer SE, Peterson BT, Kuenzig M, Hyde RW, Schwartz SI.

Surgery. 1981 May;89(5):617-21.

PMID:
7221892
48.

Goretex and autogenous vein in the canine model.

Roedersheimer LR, Cohn MS, Grauer SE, Green RM, De Weese JA.

J Cardiovasc Surg (Torino). 1980 Sep-Oct;21(5):581-9.

PMID:
7451566
49.

Response of pulmonary veins to increased intracranial pressure and pulmonary air embolization.

Peterson BT, Grauer SE, Hyde RW, Ortiz C, Moosavi H, Utell MJ.

J Appl Physiol Respir Environ Exerc Physiol. 1980 Jun;48(6):957-64.

PMID:
6769891
50.

Extrahepatic portal hypertension: a retrospective analysis.

Grauer SE, Schwartz SI.

Ann Surg. 1979 May;189(5):566-74.

Supplemental Content

Loading ...
Support Center